Thursday, July 25, 2013

Day -1

Today is my last day before a long stint, about a week, in SF which will involve several tests and blood work, the administration of both drugs, and then I should be on a weekly basis for the rest of the this first cycle of the trial.

Tuesday, July 23, 2013

Day -3 and beyond

So today I am on lead in Day -3.  It is a no drug day, and I'm feeling fine, a bit worn out from the traveling.  I returned from a round trip to SF yesterday, day -4, at 11:30 last night.  I won't be back on drug until Day 1, Friday, when I get both drugs AND a lot of tests.

Day -4 I had to be there so they could draw from PK's and PD's of the drug.  I napped most of the time, but it wasn't very restful with all the interruptions.  They take blood several times and do a bunch of EKG's watching the Qt interval which is a common side effect of this drug.  I didn't feel as fatigued by the drug, but I was napping anyway.

Day -5 and -6 were kind of rough.  I felt very fatigued and ended up sleeping a lot.  Also, the drugs seemed to have a laxative effect so I had to have a movement frequently and urgently.  Other than the fatigue I didn't have any problems with bleeding, fever, chills, or anything that they normally ask about.

Saturday, July 20, 2013

Finally Part 2

I probably should go into detail about how much trouble I had getting on the most recent trial, and maybe I will in another post, but right now I'm just so happy to say I finally was able to meet all their silly requirements to participate and today is the second day I've been on trial...  I'm in the lead in phase now which means that I am taking the newest drug everyday for 4 days.  Once the actual trial starts, it is on a intermittent schedule.

The one thing I will say about getting on this trial is that if I was asked what hell was, I would say it's what a late stage oncology patient goes through; trying to get on a promising trial and repeatedly having something come up that is infuriatingly close but prevented by a bureaucratic entities strict adherence to protocol and guidelines.

Friday, July 12, 2013

A promising article

Anti-CD47
Anti-CD47
The thing I will say about this promising breakthrough/magic bullet is that I've seen at least one very promising target in oncology turn out to be just blah, and the latent side effects make it undesirable to me;  NY-ESO-1 anyone?!??!?  Still, I'm hopeful this anti-CD47 takes off and is a successful target for oncology, I'm convinced the immune system can be harnessed to beat this terrible affliction and it can durable.